autologous 3rd generation CD19-targeting CAR T cell therapy / Uppsala University - LARVOL DELTA

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients (Clin Cancer Res) - P2 | N=24 | NCT03068416 | "Two CAR-T infusions were not better than one in the settings used in this study. As for the CAR-T infusion products, we found that effector-like CD8⁺CAR-Ts with a high polyfunctionality, high cytotoxic and cytokine production profile, and low dysfunctional signature were associated with clinical response....We identified cell-intrinsic characteristics of effector CD8⁺CAR-Ts correlating with response that could be used as an indicator for clinical outcome. The results in the study also serve as a guide to CAR-T manufacturing practices."

Cytokine release syndrome • P2 data • Hematological Malignancies • Leukemia • Oncology

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy (clinicaltrials.gov) - P2; N=24; Completed; Sponsor: Uppsala University; Active, not recruiting ➔ Completed; Trial completion date: Apr 2022 ➔ Aug 2021; Trial primary completion date: Apr 2022 ➔ Aug 2021

CAR T-Cell Therapy • Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy (clinicaltrials.gov) - P2; N=25; Active, not recruiting; Sponsor: Uppsala University; Recruiting ➔ Active, not recruiting; N=15 ➔ 25; Trial completion date: Apr 2019 ➔ Apr 2022; Trial primary completion date: Apr 2019 ➔ Apr 2022

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology